Chongkundang unit Kyungbo Pharma wins court stay on drug approval cancellations pending appeal
Bitget2026/09/30 06:31- Chongkundang Holdings issued a correction on its unit Kyungbo Pharmaceutical’s product-approval cancellation tied to a business suspension filing.
- A court granted an injunction suspending the cancellation’s effect until 30 days after the appellate ruling in the main case.
- The filing keeps the affected sales exposure at KRW 13.48 billion, equal to 5.65% of 2024 revenue.
- Suspension start date remains June 24, 2025.
- Further disclosure planned depending on the appeals court’s decision on the merits.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results
Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.
Kroger (KR.US) faces the largest layoffs in 143 years: cutting one-third of positions, more than 3,000 employees to be let go
Kroger has laid off 3,000 employees, accounting for more than one-third of its total workforce, marking the largest layoff in its 143-year history. The resources saved will be redirected towards price reductions and frontline operations.
RBA Minutes: Case for rates to act promptly to keep inflation expectations anchored
Crypto prices
More
